UNSPSC 51391740: Tazolol

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17B9PXO2SW. European Medicines Agency schedules Tobuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11135MIG. Tobuterol generally arises in the molecular formula C28H31NO5.

UNSPSC 51391740 Tazolol, a Commodity code, does not align with the recent state and local procurement activity posted under this designation. The single recent opportunity on record is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, which solicits naloxone and safe drug deactivation systems for community health initiatives—products unrelated to tazolol. The mismatch suggests either a coding error in the county's procurement system or that tazolol itself sees minimal recent activity in state and local markets. The Seminole County solicitation calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under a two-year initial term with one-year renewal option, bidder due date July 26, 2023 at 2:00 p.m.

Beyond this single opportunity, the code shows no other recent state and local solicitation activity. Vendors tracking tazolol procurement should verify whether this Commodity code continues to be used for its intended product category or whether state and local buyers have migrated tazolol purchases to a different UNSPSC classification. The absence of additional opportunities and the product mismatch in the posted record indicate limited current market activity under this code designation.